The stock closed at ₹931.90, slightly below its previous close of ₹934.30, with intraday prices ranging between ₹926.80 and ₹940.05. Over the past week, Zydus Lifesciences recorded a return of -0.66%, contrasting with the Sensex’s positive 0.96% return for the same period. Monthly performance shows a decline of 5.61% against the Sensex’s 0.86%, while year-to-date figures indicate a -3.98% return compared to the benchmark’s 8.36%. Despite these short-term fluctuations, the stock has delivered substantial gains over longer horizons, with a 3-year return of 132.28% and a 5-year return of 117.38%, outperforming the Sensex’s respective returns of 37.31% and 91.65%.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- New profitability achieved
- Growth momentum building
- Under-the-radar entry
Examining the technical indicators, the Moving Average Convergence Divergence (MACD) shows a mildly bearish signal on both weekly and monthly charts, suggesting a cautious outlook on momentum. The Relative Strength Index (RSI) presents a divergence between timeframes: no clear signal on the weekly chart but a bullish indication on the monthly chart, implying potential underlying strength over a longer period. Bollinger Bands on both weekly and monthly scales indicate bearish pressure, reflecting increased volatility and possible downward price movement.
Moving averages on the daily chart maintain a mildly bullish stance, signalling some short-term upward momentum. However, the Know Sure Thing (KST) oscillator aligns with the MACD, showing mildly bearish trends on weekly and monthly charts. Dow Theory analysis reveals a split view, with weekly data mildly bearish but monthly data mildly bullish, highlighting the complexity of the current technical landscape. On-Balance Volume (OBV) also reflects this duality, mildly bearish weekly but mildly bullish monthly, indicating mixed volume trends supporting price action.
Is Zydus Lifesciences your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- Better alternatives suggested
- Cross-sector comparison
- Portfolio optimization tool
From a market capitalisation perspective, Zydus Lifesciences holds a grade of 1, indicating its relative size within the Pharmaceuticals & Biotechnology sector. The Mojo Score currently stands at 54.0, reflecting an adjustment in evaluation from a previous grade. This technical parameter change was triggered on 19 Nov 2025, following a revision in its score on 4 Nov 2025. The stock’s day change registered a marginal decline of 0.26%, underscoring the sideways momentum observed in recent trading sessions.
Investors analysing Zydus Lifesciences should consider the interplay of these technical signals alongside broader market conditions. While short-term indicators suggest caution, longer-term metrics and historical returns highlight the stock’s capacity for substantial growth. The mixed signals from MACD, RSI, and moving averages underscore the importance of a balanced approach, favouring careful monitoring of momentum shifts and volume trends before making investment decisions.
Overall, Zydus Lifesciences presents a nuanced technical profile, with momentum oscillating between mild bullishness and bearishness across different timeframes. This complexity reflects the dynamic nature of the Pharmaceuticals & Biotechnology sector, where external factors and sectoral trends can rapidly influence stock performance. Market participants are advised to weigh these technical insights alongside fundamental analysis to fully assess the stock’s potential trajectory.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
